RECIST expert Dr. Oliver Bohnsack discusses a recent study that demonstrated the survival benefit to a subgroup of patients when irRECIST is used instead of RECIST 1.1 for image assessment in solid tumor trials, as irRECIST takes the entire tumor burden, including new tumor growth, into consideration.